Home » Newsletters » BioWorld Science

BioWorld Science

March 16, 2006

View Archived Issues

Vildagliptin absolute bioavailability determined in healthy subjects

Wex halts enrollment in phase IIb/III Tectin study on DMC's recommendation

BioSante presents Bio-E-Gel phase III data

Transition Therapeutics completes acquisition of Ellipsis Neurotherapeutics

Cook and AVI BioPharma enter NeuGene license agreement in vascular diseases

Allergan extends expiration of offer for Inamed

NM-702 increases peak walking time in intermittent claudication patients

Direct factor Xa inhibitor demonstrates antithrombotic activity in volunteers

Snapshots of recent studies of Berinert P in hereditary angioedema

Administration of HyperAcute prostate cancer vaccine feasible

Astex signs drug discovery collaboration with U. of Newcastle and CRT

OraSure comments on FDA's recommendations for studies of HIV home test kits

New sources for cardiac stem cell therapy

Bavarian Nordic expands capabilities for production of influenza vaccines

Callisto pursues dual development of atiprimod

Transition Therapeutics licenses GLP-1 patent portfolio for type 1 diabetes

Ventiv Health to change name to inVentiv Health

Spectrum eyes phase III trial for EOquin in H2 2006

NXY-059 safe and well tolerated in acute intracerebral hemorrhage study

Abbott supports development of HIV treatments for children

Studies of herbal agents in prostate cancer reported

Rosuvastatin 40 mg significantly reduces coronary atherosclerosis

Abciximab beneficial in some patients undergoing PCI with clopidogrel pretreatment

B2 induces inclusion formation: efficacy in cellular models of Huntington's and Parkinson's diseases

Phase I study of TGN-1412 suspended amid adverse events

Canadian approval for Vantas

Swedish approval for Grazax for grass pollen allergy

Novel agents for treating neurological disorders disclosed in recent patent literature

Recent patents disclose new therapeutic agents for depression, schizophrenia, etc.

Data from phase II clinical trial evaluating the HIV immunotherapeutic Vacc-4x reported

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...